Orchid Pharma Limited reported earnings results for the fourth quarter and full year ended March 31, 2024. For the fourth quarter, the company reported sales was INR 2,171.02 million compared to INR 2,099.01 million a year ago. Revenue was INR 2,304.6 million compared to INR 2,116.3 million a year ago. Net income was INR 329.56 million compared to INR 591.4 million a year ago. Basic earnings per share from continuing operations was INR 6.81 compared to INR 16.15 a year ago. Diluted earnings per share from continuing operations was INR 6.81 compared to INR 16.15 a year ago. Basic earnings per share was INR 6.81 compared to INR 14.49 a year ago. Diluted earnings per share was INR 6.81 compared to INR 14.49 a year ago.
For the full year, sales was INR 8,193.68 million compared to INR 6,658.98 million a year ago. Revenue was INR 8,502.31 million compared to INR 6,853.29 million a year ago. Net income was INR 921.67 million compared to INR 463.18 million a year ago. Basic earnings per share from continuing operations was INR 19.06 compared to INR 13.01 a year ago. Diluted earnings per share from continuing operations was INR 19.06 compared to INR 13.01 a year ago. Basic earnings per share was INR 19.06 compared to INR 11.35 a year ago. Diluted earnings per share was INR 19.06 compared to INR 11.35 a year ago.